This report presents 2 cases of renal osteodystrophy in young to middle-aged dogs, emphasizing the clinical presentation, diagnostic challenges, and therapeutic management. Both cases exhibited similar symptoms including oral abnormalities and renal dysfunction, with radiographic evidence revealing substantial bone resorption in the mandibles and maxillae. Histological analysis post-mortem confirmed advanced chronic kidney disease characterized by extensive fibrosis and glomerular abnormalities. The report underscores the critical importance of early detection of chronic kidney disease to mitigate the development of secondary hyperparathyroidism and subsequent renal osteodystrophy. These cases illustrate the complexities of diagnosing and managing renal osteodystrophy in dogs, highlighting the need for comprehensive diagnostic approaches combining clinical evaluation, radiographic imaging, and histopathological examination. Effective management strategies discussed include dietary modification, phosphate binding agents, and supportive care to alleviate clinical symptoms and slow progression of disease. The outcomes underscore the grave prognosis associated with advanced stages of chronic kidney disease and emphasize the significance of proactive screening and early intervention in mitigating renal osteodystrophy in canine patients.

Download full-text PDF

Source
http://dx.doi.org/10.1177/08987564251324114DOI Listing

Publication Analysis

Top Keywords

renal osteodystrophy
20
chronic kidney
12
kidney disease
12
osteodystrophy canine
8
canine patients
8
renal
6
patients report
4
report presents
4
presents cases
4
cases renal
4

Similar Publications

Calciprotein particles (CPPs) are blood-borne circulating nanoparticles composed of calcium phosphate and proteins that are known to exacerbate pathological processes such as chronic kidney disease-mineral bone disorder (CKD-MBD). Despite the significant interest in CKD-MBD pathogenesis, research directly addressing CPP-induced fibrosis in renal proximal tubules is rare, largely owing to the lack of suitable in vitro tissue models. Our study confirmed that 3D-cultured renal proximal tubule epithelial cells (PTECs) exhibited enhanced pathological characteristics compared to 2D-cultured PTECs when treated with CPPs, a key factor in CKD-MBD, and the uremic toxin.

View Article and Find Full Text PDF

This report presents 2 cases of renal osteodystrophy in young to middle-aged dogs, emphasizing the clinical presentation, diagnostic challenges, and therapeutic management. Both cases exhibited similar symptoms including oral abnormalities and renal dysfunction, with radiographic evidence revealing substantial bone resorption in the mandibles and maxillae. Histological analysis post-mortem confirmed advanced chronic kidney disease characterized by extensive fibrosis and glomerular abnormalities.

View Article and Find Full Text PDF

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a major complication of chronic kidney disease (CKD), characterized by disruptions in mineral metabolism, abnormal bone turnover and vascular calcification, which collectively increase the risk of fractures and cardiovascular disease. This review examines the molecular mechanisms underlying CKD-MBD, with a particular focus on the fibroblast growth factor 23 (FGF23)-Klotho axis - a key regulator of phosphate balance, vitamin D activation and parathyroid hormone secretion. In CKD, elevated FGF23 levels and reduced Klotho expression contribute to mineral homeostasis disturbances and bone abnormalities.

View Article and Find Full Text PDF

Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney disease.

CMAJ

February 2025

School of Pharmacy (Tsai, Chuang, Shao, Lai), Institute of Clinical Pharmacy and Pharmaceutical Sciences (Tsai, Chuang, Shao, Lai), College of Medicine, National Cheng Kung University, Tainan, Taiwan; Population Health Data Center (Tsai, Chuang, Shao, Lai), National Cheng Kung University, Tainan, Taiwan; Institute of Clinical Medicine (Liu), and Division of Nephrology (Liu), Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Pharmacy (Shao), Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.

Background: In patients with type 2 diabetes mellitus and chronic kidney disease (CKD), sodium-glucose cotransporter 2 (SGLT2) inhibitors improve renal outcomes, but may transiently affect biochemical markers of CKD-mineral and bone disorders (CKD-MBD). We sought to evaluate the long-term risk of CKD-MBD associated with use of SGLT2 inhibitors in this patient population.

Methods: We conducted a retrospective cohort study, employing a target trial emulation framework and using electronic medical records of patients from 9 hospitals in Taiwan (2016-2023).

View Article and Find Full Text PDF

Etelcalcetide: What we know eight years since its approval.

Nefrologia (Engl Ed)

February 2025

Department of Medicine, Faculty of Medicine, Oporto University, Alameda Prof. Hernâni Monteiro, Porto, Portugal.

Introduction And Objectives: The impact of etelcalcetide on patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) has been studied since its introduction in 2016/2017. However, only a handful of studies reported clinically relevant outcomes. This narrative review aims to summarize the published data about etelcalcetide, focusing on biochemical, cardiovascular (CV) and bone endpoints, as well as adverse effects and all-cause mortality.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!